



DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose and have indicated that their presentation or discussion will not include off-label or unapproved product usage.

Indicates that this individual's presentation(s) **will include discussion of off-label or unapproved usage.

Negar Asdaghi, M.D.
Starlie Belnap, Ph.D.
Danish Bhatti, M.D.
Nina Cruz, MSN, APRN
Karel Fuentes, M.D.
Christopher P. Kellner, M.D.
Jason Liounakos, M.D.
Linda Littlejohns R.N., MSN
Miguel A. Melo-Bicchi, M.D.

Natalia Miranda Cantellops, M.D.
Jamelah Morton, Ph.D., APRN
Regine Narchet, R.N.
Luis Orengo, M.D.
Jessily Pozo, DNP, APRN,
Charif Sidani, M.D.
Vitaly Siomin, M.D.
Justin Sporrer, M.D.
Ronald Tolchin, D.O.

Luis Felipe Tornos, M.D.
Raul Vasquez-Castellanos, M.D.
Jose Vives, M.D.
Jobyna Whiting, M.D.
Robert Wicks, M.D.
Holly Wirth, MSN, R.N.
Awss Zidan, M.D.**

Indicates that this individual's presentation(s) **will include discussion of off-label or unapproved usage.

Kevin Abrams, M.D., director for this educational activity, is a consultant for Keystone Heart and Viz.AI, and is a stockholder in Cleerly and Viz.AI.

Mary Kay Bader, R.N., MSN, is on the speakers' bureau for Ceribell, NeurOptics and BD, and is a shareholder for NeurOptics.

Selim R. Benbadis, M.D., is on the speakers' bureau for Eisai, Greenwich, LivaNova, Sunovion, Jazz Pharmaceutical; receives grant support from Cavion, LivaNova, Greenwich, SK biopharmaceuticals, Sunovion, Takeda, UCB; royalties from Emedicine-Medscape-WebMD, UpToDate; and is a consultant for Bioserenity (DigiTrace), Brain Sentinel, Cavion, Ceribell, Eisai, Greenwich, Growhealthy, LivaNova, Neuropace, SK biopharmaceuticals and Sunovion.

Guilherme Dabus, M.D., is a consultant for Cerenovus, InNeuroCo, Medtronic, Microvention, Phenox, Penumbra, Route92, Stryker and Viz.AI; is a member of the speakers' bureau for Cerenovus, InNeuroCo, Medtronic, Microvention, Penumbra, Phenox, Route92, Stryker and Viz.AI; is a stockholder in Cleerly, Hyperion, InNeuroCo, Prometheus Laboratories Inc., RIST, Synchron Three Rivers Medical, GHF and Pireaus; receives research support from SUMMIT MAX; and is a committee member for CREST-2 Interventional Management.

Felipe De Los Rios La Rosa, M.D., is on the speakers' bureau for AstraZeneca, Andexanet alfa and Brilianta.

Michael Gomez, M.D., is on the speakers' bureau for Depuy Synthes Spine.

Darryl Lau, M.D., is consultant for Atec, Cerapedics, Medtronic, NuVasive and Stryker

Italo Linfante, M.D.,** is a consultant for QApel, Cerenovus, Stryker, Medtronic, Penumbra and Prolong Pharmaceuticals.

Michael McDermott, M.D., is a consultant for Deinde Medical, Stryker, Insightec, ZAP Surgical and Light Helmets.

Robert Rothrock, M.D., is on the speakers' bureau and is a consultant for Stryker Spine.

Nicholas Theodore, M.D., is a consultant for Harvard MedTech and Globus Medical; is a shareholder for Globus Medical; and receives royalties from Globus Medical.

Diego Torres-Russotto, M.D., is a consultant for AbbVie, Acorda, IPSEN, Kyowa-Kirin, Revance, Sunovion Pharmaceuticals, Teva Pharmaceutical, Acadia Pharmaceuticals, Global Kinetics Corporation, Lunbeck, Medtronic, MERZ and Boston Scientific.

All of the relevant financial relationships listed for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development and editing/review of the content do not have relevant financial

relationships to disclose with ineligible companies*.

**Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.*